Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026
Aprea Therapeutics Inc APRE
$0.62
▼ -2.36%
($-0.02)
🎈 Low Float
🗓️ Earnings Next Week
Open
$0.64
Prev Close
$0.64
Day Range
$0.61 – $0.66
52W Range
$0.55 – $1.89
Market Cap
$7.68M
Beta
-1.24
EPS (TTM)
$-1.54
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-10-03 |
| Shares Out. | 12,380,000 |
| Website | aprea.com/ ↗ |
| Phone | 12159484119 |
| Employees | 8 |
| Net Income | -$3.3M |
| Total Assets | $47.6M |
| Total Liabilities | $5.3M |
| Equity | $41.6M |
About Aprea Therapeutics Inc
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Aprea Therapeutics Inc is a publicly traded company under the ticker symbol APRE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)